Nighttime melatonin intake increase Vitamin D levels
-
Results: Ten healthy young women between the ages of 20 and 23 were included in our study after obtaining their consent. The mean age of the participants was 21.63 ± 0.94 years. The average height of our patients was 165.72 ± 3.38 m. the average weight of our patients was 59.45 ± 3.5 kg. Vitamin D levels were significantly higher after taking melatonin (mean 13.6 ± 7.9 ng/ml) than after taking placebo (mean 12.68 ± 5.7 ng/ml) during the follicular phase (P=0.001). Whereas, the increase in vitamin D with the intake of melatonin (mean of 15.8 ± 7.8 ng/ml) compared to the taking of placebo (mean of 14.6 ± 5.7 ng/ml) was not significant during the luteal phase (P=0.7). In addition, there was no significant variation in vitamin D levels between the luteal phase and the follicular phase when taking placebo (P= 0.07) and when taking melatonin (P= 0.25).
https://www.endocrine-abstracts.org/ea/0081/ea0081ep634 -
The role of melatonin in bone regeneration: A review of involved signaling pathways
Abstract
Increasing bone resorption followed by decreasing bone mineralization are hallmarks of bone degeneration, which mostly occurs in the elderly population and post-menopausal women. The use of mesenchymal stem cells (MSCs) has raised many promises in the field of bone regeneration due to their high osteoblastic differentiation capacity and easy availability from abundant sources. A variety of compounds, including growth factors, cytokines, and other internal factors, have been combined with MSCs to increase their osteoblastic differentiation capacity. One of these factors is melatonin, whose possible regulatory role in bone metabolism and formation has recently been suggested by many studies. Melatonin also is a potential signaling molecule and can affect many of the signaling pathways involved in MSCs osteoblastic differentiation, such as activation of PI3K/AKT, BMP/Smad, MAPK, NFkB, Nrf2/HO-1, Wnt, SIRT/SOD, PERK/ATF4. Furthermore, melatonin in combination with other components such as strontium, vitamin D3, and vitamin K2 has a synergistic effect on bone microstructure and improves bone mineral density (BMD). In this review article, we aim to summarize the regulatory mechanisms of melatonin in osteoblastic differentiation of MSCs and underling involved signaling pathways as well as the clinical potential of using melatonin in bone degenerative disorders.
https://www.sciencedirect.com/science/article/abs/pii/S0300908422002127Melatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures
https://pubmed.ncbi.nlm.nih.gov/28130552/
